Application of a macrocyclization strategy in kinase inhibitor development

Acta Materia Medica · Published 2025-01-01 · DOI 10.15212/amm-2024-0070

Authors being retrieved — see the publisher record. https://doi.org/10.15212/amm-2024-0070

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Comparative drug-drug interactions of berberine and astragaloside IV in normal and type 2 diabetes mellitus rats based on UPLC-QqQ-MS/MS · Acta Materia Medica · 2025 · Same journal
Patient-derived induced pluripotent stem cell organoids for amyotrophic lateral sclerosis drug discovery · Acta Materia Medica · 2025 · Same journal
Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer · Acta Materia Medica · 2024 · Same journal
Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects · Acta Materia Medica · 2024 · Same journal
From osteoarthritis to rheumatoid arthritis: re-exploring the molecular pathways and therapeutic potential of diacerein · Acta Materia Medica · 2026 · Same journal
Antineoplastic effects of icaritin: molecular mechanisms and applications · Acta Materia Medica · 2025 · Same journal
Exploring food and medicine homology: potential implications for cancer treatment innovations · Acta Materia Medica · 2025 · Same journal
Macrophage differentiation in enhancing hematopoietic function of ribonucleic acid for injection II via multi-omics analysis · Acta Materia Medica · 2024 · Same journal
Preliminary study on Zeqi: from pharmacological action of active ingredients to clinical application research · Acta Materia Medica · 2024 · Same journal
Vicatia thibetica de Boiss root extract and its active constituents attenuate skin aging induced by D-galactose and glucocorticoid · Acta Materia Medica · 2026 · Same journal